IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Featured in Benzinga Article Evaluating Potential of Cannabinoids in Treating Alzheimer’s

On Thursday, India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, was featured in an article on Benzinga titled ‘Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work’. The article notes that soon after discovering the pathway by which low-dose THC binds to amyloid beta plaques and prevents them from aggregating on neurons, the University of South Florida filed a patent for that mechanism. Notably, IGC announced on June 12 that it had acquired exclusive rights to this patent, titled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’, positioning the company to protect a potential cannabis-based blockbuster treatment for America’s most expensive disease. “What IGC is going to do with this patent is take it to clinical trials,” Ram Mukunda, CEO of IGC, stated in the Benzinga article. “We have productized it, and there is more than sufficient evidence. So, now we are now talking to several different places to see where we can begin clinical testing on the path to FDA approval.” If FDA approval is achieved, the market potential for a THC-based Alzheimer’s treatment could be expansive. There are currently more than 5.3 million Americans living with Alzheimer’s, and Medicare and Medicaid alone are expected to spend $175 billion on Alzheimer’s patients in 2017.

To view the full Benzinga article, visit http://nnw.fm/K0JdW

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us